Telix Pharmaceuticals TLPPF Stock
Telix Pharmaceuticals Price Chart
Telix Pharmaceuticals TLPPF Financial and Trading Overview
| Telix Pharmaceuticals stock price | 7.68 USD |
| Previous Close | 7.39 USD |
| Open | 7.73 USD |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 7.52 - 7.73 USD |
| 52 Week Range | 2.75 - 8.08 USD |
| Volume | 1.28K USD |
| Avg. Volume | 5.27K USD |
| Market Cap | 2.41B USD |
| Beta (5Y Monthly) | 2.317624 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0.02 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
TLPPF Valuation Measures
| Enterprise Value | 2.23B USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 15.056099 |
| Price/Book (mrq) | 29.703558 |
| Enterprise Value/Revenue | 13.958 |
| Enterprise Value/EBITDA | -32.545 |
Trading Information
Telix Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 2.317624 |
| 52-Week Change | 173.27% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 8.08 USD |
| 52 Week Low | 2.75 USD |
| 50-Day Moving Average | 6.95 USD |
| 200-Day Moving Average | 5.04 USD |
TLPPF Share Statistics
| Avg. Volume (3 month) | 5.27K USD |
| Avg. Daily Volume (10-Days) | 2.96K USD |
| Shares Outstanding | 318.53M |
| Float | 246.32M |
| Short Ratio | N/A |
| % Held by Insiders | 27.58% |
| % Held by Institutions | 13.25% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -65.010% |
| Operating Margin (ttm) | -45.71% |
| Gross Margin | 61.55% |
| EBITDA Margin | -42.88% |
Management Effectiveness
| Return on Assets (ttm) | -25.050% |
| Return on Equity (ttm) | -253.34% |
Income Statement
| Revenue (ttm) | 160.1M USD |
| Revenue Per Share (ttm) | 0.52 USD |
| Quarterly Revenue Growth (yoy) | 2803.30% |
| Gross Profit (ttm) | 98.54M USD |
| EBITDA | -68662000 USD |
| Net Income Avi to Common (ttm) | -104079000 USD |
| Diluted EPS (ttm) | -0.24 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 116.33M USD |
| Total Cash Per Share (mrq) | 0.37 USD |
| Total Debt (mrq) | 10.45M USD |
| Total Debt/Equity (mrq) | 13.06 USD |
| Current Ratio (mrq) | 2.025 |
| Book Value Per Share (mrq) | 0.253 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -63970000 USD |
| Levered Free Cash Flow (ttm) | -30140376 USD |
Profile of Telix Pharmaceuticals
| Country | United States |
| State | VIC |
| City | North Melbourne |
| Address | 55 Flemington Road |
| ZIP | 3051 |
| Phone | 61 3 3093 3897 |
| Website | https://telixpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 234 |
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials for the treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with Mauna Kea Technologies and Lightpoint Medical to develop advanced image and radio-guided surgical technologies. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Q&A For Telix Pharmaceuticals Stock
What is a current TLPPF stock price?
Telix Pharmaceuticals TLPPF stock price today per share is 7.68 USD.
How to purchase Telix Pharmaceuticals stock?
You can buy TLPPF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Telix Pharmaceuticals?
The stock symbol or ticker of Telix Pharmaceuticals is TLPPF.
Which industry does the Telix Pharmaceuticals company belong to?
The Telix Pharmaceuticals industry is Biotechnology.
How many shares does Telix Pharmaceuticals have in circulation?
The max supply of Telix Pharmaceuticals shares is 342.06M.
What is Telix Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Telix Pharmaceuticals PE Ratio is 384.00000000 now.
What was Telix Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Telix Pharmaceuticals EPS is 0.02 USD over the trailing 12 months.
Which sector does the Telix Pharmaceuticals company belong to?
The Telix Pharmaceuticals sector is Healthcare.